CYTOMX THERAPEUTICS I

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

08 أغسطس 2023 16:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

01 أغسطس 2023 08:00:02 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

20 يوليو 2023 09:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

17 يوليو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

30 يونيو 2023 08:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

01 يونيو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

09 مايو 2023 16:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

01 مايو 2023 16:01:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

25 أبريل 2023 16:05:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

27 مارس 2023 16:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

22 مارس 2023 19:23:33 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming March Investor Conferences

28 فبراير 2023 16:05:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

26 يناير 2023 07:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

17 يناير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

05 يناير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

05 يناير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

22 ديسمبر 2022 17:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

20 ديسمبر 2022 17:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

07 ديسمبر 2022 16:30:00 بحسب Nasdaq GlobeNewswire

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

17 نوفمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire